Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $330
Benzinga Newsdesk 10 hours ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $326 to $330.
Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $326 to $330.